Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sarepta Therapeutics, Inc.
Age
4–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Has completed a study of SRP-5051 and continues to meet the Eligibility Criteria of Study 5051-102.
You may not be if
Initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) since completing a study administering SRP-5051 and while participating in this study for any of the following: angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs), beta-blockers, potassium and steroids\*.
Requires antiarrhythmic and/or diuretic therapy for heart failure.
Use of any herbal medication/supplement containing aristolochic acid.
Treatment with any experimental therapy since entering original study or any experimental gene therapy for the treatment of DMD at any time.
Participation in an interventional clinical trial since completing original study.
\* The dose of steroids must remain constant except for modifications to accommodate changes in weight.
Clareo Health | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
